We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
USA - September 28 2012
Isolated DNA molecules are patent-eligible, reaffirmed the U.S. Court of Appeals for the Federal Circuit, lifting a cloud of uncertainty over DNA composition patents—at least for now.
USA - August 30 2012
Addressing for the first time the role of a district court to remedy an improper use code submitted to the U.S. Food and Drug Administration (FDA), the U.S. Court of Appeals for the Federal Circuit held that a federal court’s powers are limited to enjoining an improper use code and that the party is “given the opportunity to propose the specific language of the use code.”
USA - August 21 2012
A panel of the U.S. Court of Appeals for the Federal Circuit endorsed patent-eligibility of DNA molecules in a decision much awaited by the biotechnology community.
USA - May 30 2012
The U.S. Supreme Court has now addressed for the first time the scope of a statutory provision authorizing generic drug companies to counterclaim in Hatch-Waxman litigation against a branded company to correct or delete patent information submitted to the U.S. Food and Drug Administration (FDA) and listed in the Orange Book.
USA - March 22 2012
In a move that could have a significant impact on the fields of personalized medicine and medical diagnostics, the Supreme Court of the United States recently held claims to a blood test were invalid because they did not define patent-eligible subject matter.
